Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.65 |
| ▸ | TPMT | P51580 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413369 | 0.89 | TTR (0.59) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL26095257 | 0.89 | TTR (0.59) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL23699468 | 0.87 | TTR (0.52) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL8840346 | 0.87 | TTR (0.52) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL11556678 | 0.81 | TTR (0.76) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL7263572 | 0.81 | TTR (0.68) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL31214608 | 0.79 | TTR (0.65) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL543454 | 0.79 | TTR (0.65) | TTRTPMTTSHRSRD5A2HCAR1 | |
| Fluoride SCHEMBL27668632 | 0.79 | TTR (0.65) | TTRTPMTTSHRSRD5A2HCAR1 | |
| SCHEMBL737305 | 0.79 | TTR (1.00) | TTRTPMTTSHRSRD5A2HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863850-B | Biaryl compound and preparation method and application thereof | 复旦大学 | 2021-05-18 | — | — | CN | disclosed |
| US-10844017-B2 | Biaryl compound, preparation method and use thereof | FUDAN UNIVERSITY (CN) | 2020-11-24 | — | — | US | disclosed |
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2004013100-A2 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | WO | disclosed |
| EP-0279698-A2 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844017-B2 | Biaryl compound, preparation method and use thereof | RORC, RORB, RORA | TTR 4248/4885TPMT 972/4885TSHR 1058/4885 |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | TTR 3138/4885TPMT 4819/4885TSHR 44/4885 |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | TTR 2388/4885TPMT 4772/4885TSHR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.